Correction to: Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies

T. Joseph Mattingly II¹ · R. Brett McQueen² · Pei-Jung Lin³

Published online: 25 January 2022

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Correction to: *PharmacoEconomics* (2021) 39:1101–1107
<https://doi.org/10.1007/s40273-021-01079-6>

This work was funded by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The original article has been corrected.

In this article the statement in the Funding information section was incorrectly given as

Funding

This work was in part funded by the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation's Value Assessment Initiative.

It should have read

The original article can be found online at <https://doi.org/10.1007/s40273-021-01079-6>.

✉ T. Joseph Mattingly II
jmattingly@rx.umaryland.edu

¹ Patient-Driven Values in Healthcare Evaluation (PAVE) Center at the University of Maryland School of Pharmacy, 220 Arch Street, 12th Floor, Room 224, Baltimore, MD 21201, USA

² Pharmaceutical Value (pValue) Initiative at the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

³ Center for the Evaluation of Value and Risk in Health (CEVR), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA